PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer
VERSATILE-002 is studying two groups of HPV16-positive head and neck cancer patients whose cancer has returned or spread.
- VERSATILE-002 is studying two groups of HPV16-positive head and neck cancer patients whose cancer has returned or spread.
- The first group has not been previously treated with a checkpoint inhibitor (CPI nave).
- The second group of patients have failed multiple treatments including checkpoint inhibitor therapy (CPI refractory).
- As specified in the clinical trial design, objective response is measured by radiographic tumor responses according to RECIST 1.1 (tumor reduction of 30% or more).